abstract |
A humanized bispecific anti-HER 2 antibody comprising one antigen-binding site comprising trastuzumab heavy and light chain variable regions and another antigen-binding site comprising pertuzumab heavy and light chain variable regions. The bispecific anti-HER 2 antibodies are effective in treating cancer, such as breast, gastric, or ovarian cancer. Preferred bispecific anti-HER 2 antibodies are nonfucosylated antibodies. Also provided are Chinese Hamster Ovary (CHO) mutant cell lines having a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation. |